A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy

AIDS

Volumn 14, Issue 9, 2000, Pages

  Baxter, John D ^a,l   Mayers, Douglas L ^b   Wentworth, Deborah N ^c   Neaton, James D ^c   Hoover, Marie L ^d   Winters, Mark A ^e   Mannheimer, Sharon B ^f   Thompson, Melanie A ^g   Abrams, Donald I ^h   Brizz, Barbara J ⁱ   Ioannidis, John P A ^j,k   Merigan, Thomas C ^d   Pettinelli, C ^j   Canady, K ^m   Johnston Dow, L ⁿ   Perille, E ^o   Bohn, H ^g   Martinez, A ^j   Munk, R ^l   Day, T ^l   Lukac, S ^p   Weislow, K ^q   George, K ^q   Gallahan, D ^q   Sioud, M ⁱ   more..

^a Department of Anesthesiology   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d Laboratory of Molecular and Cellular Biology of Hematopoiesis   (United States)

^e STANFORD UNIVERSITY   (United States)

^f HARLEM HOSPITAL CENTER   (United States)

^g AIDS Research Consortium of Atlanta   (United States)

^h SAN FRANCISCO GENERAL HOSPITAL   (United States)

ⁱ SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^j NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^k UNIVERSITY OF IOANNINA   (Greece)

^l Education and Research Building ^*

^m Pharmaceutical Product Development   (United States)

ⁿ APPLIED BIOSYSTEMS   (United States)

^o Appl Biosystems Div of Perkin E ^*  (United States)

^p Southern New Jersey AIDS Clinical Trials   (United States)

^q SRA Technologies Inc   (United States)

more..

Author keywords

Antiretroviral therapy; HIV drug resistance resistance mutations; Viral load

Indexed keywords

INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESISTANCE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MUTATION; RNA, VIRAL; VIRAL LOAD;

EID: 0033920318     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200006160-00001     Document Type: Article

References (30)

1. 1. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. JAMA 1998, 279:1984-1991.
2. 2. Tudor-Williams G, St Clair MH, McKinney RE, et al. HIV-1 sensitivity to zidovudine and clinical outcome in children. Lancet 1992, 339:15-19.
3. 3. Principi N, Marchisio P, DePasquale MP, Massironi E, Tornaghi R, Vago T. HIV-1 reverse transcriptase codon 215 mutation and clinical outcome in children treated with zidovudine. AIDS Res Hum Retroviruses 1994, 10:721-726.
4. 4. Kozal MJ, Shafer RS, Winters MA, Katzenstein DA, Merigan TC. A mutation in HIV reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis 1993, 167:526-532.
5. 5. Japour AJ, Welles S, D'Aquila RT, et.al. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. J Infect Dis 1995, 171:1172-1179.
6. 6. Patick AK, Zhang M, Hertogs K, et al. Correlation of virological response with genotype and phenotype of plasma HIV-1 variants in patients treated with nelfinavir in the US expanded access program. Second International Workshop on HIV Drug Resistance and Treatment Strategies. Lake Maggiore, June 1998 [abstract 57].
7. 7. Harrigan PR, Montaner JS, Hogg RS, et al. Baseline resistance profile predicts response to ritonavir/saquinavir therapy in a community setting. Second International Workshop on HIV Drug Resistance and Treatment Strategies. Lake Maggiore, June 1998 [abstract 55].
8. 8. Zalopa AR, Shafer RW, Warford A, Montoya JG, Katzenstein D, Merigan TC. Predictors of antiviral response to saquinavir/ritonavir therapy in a clinical cohort who failed prior protease inhibitors; a comparison of clinical characteristics, antiretroviral drug history and HIV genotype. Second International Workshop on HIV Drug Resistance and Treatment Strategies. Lake Maggiore, June 1998 [abstract 54].
9. 9. Deeks SG, Parkin N, Petropoulos CJ, et al. Correlation of baseline phenotypic drug susceptibility with 16 week virologic response in a pilot combination therapy study in HIV-infected patients who failed indinavir therapy. Second International Workshop on HIV Drug Resistance and Treatment Strategies. Lake Maggiore, June 1998 [abstract 53].
10. 10. Mellors JW, Larder BA, Schinazi RF. Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance. International Antiviral News. 1995, 3:8-13.
11. 11. Cockerill III FR. Genetic methods for assessing antimicrobial resistance. Antimicrob Agents Chemother 1999, 43:199-212.
12. 12. Kellam P, Larder BA. Recombinant virus assay: a rapid phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrobial Agents Chemother 1994, 38:23-30.
13. 13. Erice A, Mayers DL, Strike DG, et al. Brief Report: primary infection caused by zidovudine-resistant human immunodeficiency virus type 1 (HIV-1). N Engl J Med 1993, 328: 1163-1165.
14. 14. Fang G, Burger H, Grimson R, et al. Maternal plasma HIV-1 RNA level: A determinant and threshold for mother-to-child transmission. Proc Natl Acad Sci USA 1995, 92:12100-12104.
15. 15. Fitzgibbon JE, Gaur S, Frenkel LD, Laraque F, Edlin BR, Dubin DT. Transmission from one child to another of human immunodeficiency virus type 1 with a zidovudine resistance mutation. N Engl J Med 1993, 329:1835-1841.
16. 16. Frenkel LM, Wagner LEI, Demeter LM, et al. Effects of zidovudine use during pregnancy on resistance and vertical transmission of human immunodeficiency virus type 1. Clin Infect Dis 1995, 20:1321-1326.
17. 17. Mayers DL, Yerly S, Perrin L, et al. Prevalence of AZT-resistant (AZT) HIV-1 in persons seroconverting in Switzerland, Australia, and the United States between 1988 and 1994. 2nd National Conference on Human Retroviruses and Related Infections. Washington, January 1995 [abstract 385].
18. 18. Hecht HM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl Med 1998, 339:307.
19. 19. Durant J, Clevenbergh P, Halfon P, et al. Drug resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999, 353:2195-2199.
20. 20. Saag MS, Holodniy M, Kuritzkes DR, et al. HIV viral load markers in clinical practice. Nature Med 1996, 2:625-629.
21. 21. Brambilla D, Leung S, Lew J, et al. Interkit differences in plasma HIV-1 RNA levels in mothers enrolled in WITS/ACTG 078 Fourth Conference on Retroviruses and Opportunistic Infections. Washington, January 1997 [abstract 616].
22. 22. Winters MA, Cooley KL, Girard YA, et al. A 6-base pair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest 1998, 102:1769-1775.
23. 23. Wisconsin Package Version 9.1. Madison: Genetics Computer Group (GCG); 1997.
24. 24. Carpenter CJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997:updated recommendations of the International AIDS Society-USA panel. J Am Med Assoc 1997, 277:1962-1969.
25. 25. Department of Health and Human Services and Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV infected adults and adolescents. MMWR 1998, 47: 43-82.
26. 26. Carpenter CJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA panel. J Am Med Assoc 1998, 280:78-86.
27. 27. Deeks SG, Grant RM, Beatty GW, et al. Activity of ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure. AIDS 1998, 12: F97-F102.
28. 28. Ait-Khaled M, Rakik A, Thomas D, et al. HIV-1 baseline genotype/phenotype and virological response following salvage therapy with Ziagin (Abacavir, ABC), Amprenavir (APV), and Sustiva (Efavirenz, EFV). Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1999 [abstract 133].
29. 29. Gallant JE, Hall C, Branett S, Raines C. Ritonavir/saquinavir as salvage therapy after failure of initial protease inhibitor regimen. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 427].
30. 30. Tebas P, Kane E, Lebert M, et al. Virologic response to ritonavir/saquinavir containing regimen in patients who have previously failed nelfinavir. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 510].